Navigation Links
New Study Building Framework to Bring Personalized Medicine to the Clinic
Date:2/2/2012

TORONTO, Feb. 2, 2012 /PRNewswire/ -- Dr. Tom Hudson, President and Scientific Director of The Ontario Institute for Cancer Research (OICR), today announced a new study to develop a framework for the implementation of personalized medicine in cancer care.

The framework aims to integrate genomics research into everyday clinical practice, with a goal to provide improved and more targeted care for patients.

Published in the journal Cell, the framework supports improved diagnostics for cancer patients based on DNA analyses of tumours. The results of these analyses could be used to predict a patient's response to novel therapies. More immediately, it could be used to predict how drugs currently approved and in use today could help to treat other types of cancer.

"As the cost of genome sequencing decreases, we are presented with the reality that soon genome analysis will be no more or less expensive than most diagnostic tests in use today," said Dr. Hudson. "This presents a huge opportunity to improve diagnosis for patients and ultimately improve patient outcomes. But in order to implement these tools, we must first understand their impact in a clinical setting."

"This framework is not about simply doing a new test but creating evidence that would inform what type of treatment would be given to individual patients," said Dr. Janet Dancey, leader of OICR's High Impact Clinical Trials Program. "We currently have a strong theoretical basis but now we need to create evidence from clinical trials to put these theories into clinical practice."

"The timing is right to develop a clinical trial and research framework for genomics and cancer," said Dr. Philippe L. Bedard, Medical Oncologist at Princess Margaret Hospital. "This framework will help to deliver on the promise of personalized medicine sooner."

The paper's publication coincides with World Cancer Day on February 4, 2012. The collaborative research conducted in the study is an excellent example this year's World Cancer Day theme "Together it is possible". For more information on World Cancer Day visit www.worldcancerday.org.

Much of the work in the study is based on sequencing currently underway by the International Cancer Genome Consortium (ICGC), a collaborative international effort with a goal of sequencing 25,000 tumours from 50 different cancer types. The ICGC is creating a large database of mutations that are revealing many mutations known to be involved in specific tumours (for example, the BRAF mutation) are observed in many other types of cancer. This suggests that cancer diagnosis should involve an in-depth analysis of a tumour's mutation for many different types of cancer, regardless of where the tumour originated.

While the framework does provide a path forward for establishing a role for genomics in everyday clinical practice in the future, more research is needed before such practices can be implemented more widely.

Cancer was once thought of as a single disease that affected many different parts of the body. Now researchers know that every patient's cancer is different, requiring different treatments for different patients – even for tumours of the same type of cancer. This means new technologies are required to accurately diagnose and effectively treat different types of cancer. Personalized medicine will allow physicians to use new tools to identify characteristics of a tumour that are specific to each patient, and then tailor treatment to each patient's specific form of the disease. This will lead to earlier, more accurate diagnosis and improved treatment for patients with fewer side effects.

OICR

OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation, launched by the Government of Ontario in 2005. The annual budget for OICR, its research partners and collaborators exceeds $160 million. This supports more than 1,500 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academia across the Province of Ontario. It has research hubs in Hamilton, Kingston, London, Ottawa, Thunder Bay and Toronto. OICR has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase III clinical trials. For more information, please visit the website at www.oicr.on.ca.

Princess Margaret Hospital

Princess Margaret Hospital and its research arm, Ontario Cancer Institute, have achieved an international reputation as global leaders in the fight against cancer and delivering personalized cancer medicine. Princess Margaret Hospital, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital and Toronto Rehabilitation Institute. All are research hospitals affiliated with the University of Toronto. For more information, go to www.uhn.ca

 


 


'/>"/>
SOURCE Ontario Institute for Cancer Research
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
2. Nature Materials study: Graphene invisible to water
3. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
4. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
5. Carnegie Mellon study reveals potential of manganese in neutralizing deadly Shiga toxin
6. Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
7. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
8. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
9. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
10. Study finds chronic abnormal brain blood flow in Gulf War veterans
11. Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):